Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 7th 2015

Night Shift Work Is Not Heart Healthy, Study Finds

A new study has identified an increased risk of lung cancer and heart disease in night shift workers, adding to the growing knowledge of health risks associated with those jobs.

January 7th 2015

Cancer: A Genetic Gamble

A paper published in Science Magazine this month, co-authored by a mathematician and a biologist, suggests that heredity and environmental factors account for only one-third of the risk for developing cancer. A majority of risk is associated with random mutations, a result of mistakes during normal cellular replication.

January 6th 2015

Cancer Patients Not Too Distressed by Advanced Directives

A study conducted at the humanities and medicine departments at Penn State College of Medicine in Hershey, Pennsylvania, found that there's never an ideal time to talk to cancer patients about end-of-life decisions, and most patients are not too disturbed by these discussions.

January 6th 2015

Nanotechnology for Surgical Success and Phototherapy in Cancer

Scientists at Oregon State University have developed fluorescent nanoparticles that can aid in the removal of malignant tumors and also kill any remaining malignant cancer cells.

January 5th 2015

Will Neupogen Prove the Poster Child for Increased Access to Cheaper Biosimilars?

If the biological developed by Novartis to imitate Amgen's Neupogen is approved by the FDA, it'd open floodgates as other biosimilars find their way to the FDA's doorsteps. The cheaper alternatives would prove a tremendous cost-saving to the healthcare industry.

January 3rd 2015

ACA Can Help Smokers Quit, Experts Write

A perspective published in the New England Journal of Medicine affirms that provisions of the Affordable Care Act will allow improved coverage of smoking cessation tools, which could be a big boost in the number of smokers planning to quit.

January 3rd 2015

More Than 1.5 Million Cancer Deaths Averted in Last 2 Decades

Rates of cancer deaths have declined 22% over the last 2 decades, which amounts to 1.5 million deaths averted, according to the annual cancer statistics report from the American Cancer Society.

January 3rd 2015

NICE Uses Comparitive Effectiveness for Nab-Paclitaxel in Pancreatic Cancer

NICE has published draft guidance which recommends that nab-paclitaxel given with gemcitabine should not be funded by the NHS for previously untreated metastatic pancreatic cancer, because its limited benefits compared to current treatments do not justify its cost.

January 1st 2015

A New Hope in Advanced Lung Cancer

Combining erlotinib with SBRT more than doubled the survival time of stage 4 lung cancer patients.

December 30th 2014

The Year in Review: Most-Read Stories of 2014

Laura Joszt, MA

With 2014 coming to a close, The American Journal of Managed Care is taking a look back at the most popular articles from this year. These most-read articles highlight the healthcare issues most important to providers, insurers, and policy makers.

December 28th 2014

Blackberry Competes With Apple for Healthcare Apps

Blackberry announced the product of their collaboration with NantHealth: a healthcare app for doctors and nurses who use their smartphones.

December 27th 2014

Gardasil 9 Approved for 5 Additional HPV Types

With this approval, the vaccine can effectively protect against 5 additional types of HPV than the parent Gardasil vaccine, thereby preventing the development of cervical, vulvar and vaginal cancers, based on a randomized clinical trial.

December 27th 2014

Immuno-Oncology Getting Closer to Being Personalized: Nature Study

The Nature letter published results showing that the monoclonal antibody targeting PD-1 had antitumor activity, but more importantly, the response was greater in patients overexpressing the PD-L1 receptor, thereby opening the doors for targeted therapy.

December 21st 2014

ASCO Releases Guidelines to Improve Patient Awareness and Participation in Phase I Trials

The American Society of Clinical Oncology called for greater access to and education about phase I clinical trials, the first-in-human studies of new agents designed to fight cancer.

December 21st 2014

Lanreotide Approved for Gastroenteropancreatic Neuroendocrine Tumors

The approval was based on the results of a clinical trial that demonstrated improved PFS in patients on lanreotide. While the median PFS in the placebo arm was 16 months, patients in the lanreotide arm had not yet reached median PFS at the time of analysis, and it was anticipated to extend beyond 22 months.

December 20th 2014

Bayer's Xofigo Gains NICE Approval

The National Institute for Health and Care Excellence has issued draft guidelines on using the drug in prostate cancer patients.

December 17th 2014

Treatment Decisions and Unmet Needs

December 17th 2014

Anti-Androgens and Combination Regimens in CRPC

December 17th 2014

Early Indication of Androgen Deprivation Resistance

December 17th 2014

Diagnostic and Prognostic Biomarkers

December 17th 2014

Episode 3 - The CHAARTED Study-Treatment of CRPC with Docetaxel

December 17th 2014

Episode 2 - Variability in Disease Course and Treatment Approach

December 17th 2014

Episode 1 - Defining and Detecting CRPC

December 17th 2014

AJMC Session Traces Evolution of ACO Growth, Mental Health Delivery Models

How do ACOs reach the point of delivering both savings and better care? The recent online session of the ACO and Emerging Healthcare Delivery Coalition, sponsored by The American Journal of Managed Care, covered how ACOs evolve, how that process applies to oncology care, and how managed care can benefit from a better model for mental health delivery.

December 16th 2014

Alex Bastian Strives to Define Value in Care Better

In order to reign in high costs of care in oncology, the healthcare community needs to be able to define value better, according to Alex Bastian, MBA, senior vice president at GfK.

December 15th 2014

UnitedHealth Launches Bundled Payment Program at MD Anderson

The pilot, which will has been launched for head and neck cancer patients, will include quality measures to ensure adequate patient care.

December 14th 2014

After Astra, Pfizer Taps Other Immuno-Oncology Markets

With the immuno-oncology field getting more intense, Pfizer continues its struggle to gain a foothold in the field. Following unsuccessful attempts to bid for AstraZeneca, Pfizer has now signed a deal with a Belgian company, iTeos Therapeutics.

December 13th 2014

How Should E-Cigarettes Be Regulated?

Should e-cigarettes be regulated he same way as cigarettes? Should marketing and sales restrictions be the same? Policy and health experts chime-in.

December 13th 2014

Hopkins Adapts to Prevent Cancer Risk of Uterine Morcellation

Just prior to the FDA guidance on the use of power morcellators, Johns Hopkins made public a new care plan for managing fibroids or hysterectomies in women over age 50 years.

December 13th 2014

Making a Case for Biomarkers in Cancer Immunotherapy

Immune response boosters in oncology, approved for melanoma so far, are being evaluated in several different cancer types. While the drugs perform well, there is a definite need to identify responsive patient cohorts.

...

142 143 144 145 146 147 148 149 150

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions